Navigation Links
AFcell Medical Hires Chief Operating Officer
Date:4/18/2013

WEST CONSHOHOCKEN, Pa., April 18, 2013 /PRNewswire/ -- AFcell Medical, the leading innovator and designer of surgical birth tissue forms as marketed under its AmnioClear brand, is proud to announce the hiring of David Buche as Chief Operating Officer.

Mr. Buche, who has more than 25 years experience in the biologics and medical device industry, joins AFcell Medical where he will lead new product development, sales force expansion and strategic growth activities.

Most recently Mr. Buche was with Integra Life Sciences as Vice President, Marketing and Product Development, Instruments.  Mr. Buche led a team of marketing, research & development, project and regulatory experts who were responsible for driving new products to the market through multiple sales channels for the $180 million division.

Prior to joining Integra, Mr. Buche was Vice President and Chief Operating Officer for a 170 employee division of Synovis Life Technologies.  During his 15 year tenure at Synovis, Mr. Buche led consistent growth by driving several new biological products to market, leading the commercialization of a new, regenerative biological technology platform and driving sales growth through exceptional surgical community interaction and sales force expansion. 

Prior to Synovis, Mr. Buche held various sales and marketing positions for the Spectranetics Corporation.  Spectranetics develops, manufactures and markets laser equipment and single use interventional devices for treating arterial disease.

Mr. Buche served in the US Navy, received executive education from the University of Minnesota, Carlson School of Business and an advanced degree from California Coast University. 

Said Robin Young , CEO and Founder of AFcell Medical; "David's extensive experience bringing biologic products to market and commercializing regenerative biologic technology platforms fits well with AFcell Medical's culture of innovation for general surgery, wound care and orthopaedic indications.  As we continue to build out our team, AFcell is committed to taking competitive share, creating KOL support and delivering exceptional financial results which will, I think, serve all of AFcell's stakeholders well."

New Chairman of the Board

Mr. Buche joins AFcell a few weeks after AFcell's board of directors elected Olivier Carli as its new chairman.

Mr. Carli is the President of Denos, Ltd and founder of Ideal Medical – one of the largest healthcare services companies in the world.  Companies which Mr. Carli has founded or led have all become market leaders in more than 64 countries by commercializing creative and cost effective healthcare delivery, medical device and biologic product solutions to physicians and patients. 

In the United States, Mr. Carli is perhaps best known as the founder of Scient'x Medical which was later acquired by Alphatec Spine. Scient'x was justifiably well known as one of the leading innovators of spinal implants in the world. As CEO of Scient'x, Mr. Carli drove spinal innovation along several pathways including motion preservation, dynamic stabilization and minimally invasive tools and instruments.  In addition, Mr. Carli was on the forefront of surgeon education with his popular Inspiration Educational Meetings.

Overall, Mr. Carli's companies have distribution or healthcare service delivery in France, Europe, Russia, Malaysia, China, South Africa, Brazil, Libya, Argentina and approximately 60 other countries.

About AFcell Medical
AFcell Medical Inc., is a leading supplier of birth tissue products for use in the clinical setting. Its processing partner is the Musculoskeletal Transplant Foundation (MTF), the leading tissue bank and processor of allograft tissues in North America and Europe. AFcell Medical, with headquarters in West Conshohocken, PA, supplies its trademarked AmnioClear® amniotic allograft tissue to hospitals throughout the United States.

For more information contact: 
AFcell Medical 
mailto:info@afcellmedical.com   
Or visit our web site at  
http://www.afcellmedical.com

AmnioClear® is a registered trademark of AFcell Medical Inc.


'/>"/>
SOURCE AFcell Medical
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
2. OHK Medical Devices appoints Mr. Omer Inbar as Chief Executive Officer
3. Maryville, Tennessee Based Molecular Pathology Laboratory Network (MPLN) Celebrates 38th Annual Medical Laboratory Professional Week by Honoring Employees
4. Nebraska Medical Center Implants States First SynCardia Total Artificial Heart
5. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
6. BioClinica Releases Integrated Medical Image Management Solution
7. Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
8. AtheroNova Adds New Medical Advisor
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
11. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Allergan plc (NYSE: ... announced that Brent Saunders , Allergan,s CEO and ... a fireside chat session at the RBC Capital Markets ... p.m. ET at The New York Palace Hotel in ... will be webcast live and can be accessed on ...
(Date:2/10/2016)... ... 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will feature ... in San Francisco’s Moscone Center from February 16-18, 2016, and at the healthcare-focused ... latest InGaAs PIN diode standard packages feature a TO-46 metal can with active areas ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... medicine, has announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) ... the Philippines, Thailand and Singapore in the latest adipose and bone marrow therapies. ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):